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The new  consensus  statement  on  the  care  of  hyperglycaemic  and  diabetic  patients  with
an  acute  coronary  syndrome  (ACS)  [1]  represents  a  considerable  effort  to  provide  clini-
cian  cardiologists  with  guidance  in  the  management  of  their  patients.  It  is  a  remarkable
achievement.
Several  points  are  of  particular  importance,  on  which  the  consensus  provides  up-to-
date  reviews  that  make  an  important  addition  to  current  literature.  Conversely,  as  in  all
consensus  documents  or  guidelines,  some  of  the  proposed  recommendations  are  undoubt-
edly  debatable,  in  particular  when  these  are  put  in  the  context  of  current  practices  in
France.
In  the  ﬁrst  category  is  the  emphasis  put  on  the  high  prevalence  of  glucose  metabolism
disorders  in  patients  with  coronary  artery  disease  admitted  with  an  acute  coronary  event.
In  recent  surveys  in  France,  the  prevalence  of  known  diabetes  mellitus  at  the  time  of  anaigu
acute  myocardial  infarction  (AMI)  is  around  20—22%  [2].  This  ﬁgure  actually  underestimates
the  true  prevalence  of  diabetes,  as  it  is  now  widely  recognised  that,  even  in  France  [3],
the  proportion  of  patients  without  recognised  diabetes  is  high  in  those  presenting  with  an
ACS.
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The  pathophysiological  signiﬁcance  and  prognostic
mportance  of  hyperglycaemia  at  the  acute  stage  is  also
nderlined.  In  brief,  all  evidence  concurs  in  showing  the
eleterious  prognostic  signiﬁcance  of  a  hyperglycaemic
tate,  which  may  represent  both  a  true  underlying  metabolic
isorder  but  also  a  marker  of  acute  stress  and  profound
yocardial  injury.  As  pointed  out  in  the  text,  hypergly-
aemia  has  a  deleterious  prognostic  signiﬁcance,  both  in
atients  with  and  in  those  without  recognised  diabetes  [4].
The  consensus  document  also  carefully  reviews  the
esults  of  trials  having  assessed  the  role  of  insulin  ther-
py  at  the  acute  stage  and  emphasizes  the  potential  risk  of
ypoglycaemia  in  situations  of  acute  myocardial  ischaemia.
Finally,  the  text  gives  a  welcome  overview  of  the  beneﬁts
f  rehabilitation  after  an  acute  coronary  event,  of  nutri-
ional  counselling,  and  of  when  patients  should  be  referred
o  a  diabetologist.  All  of  these  points  are  particularly  rel-
vant,  and  the  consensus  statement  provides  a  very  useful
nd  state-of-the-art  review  of  our  current  knowledge  in  this
eld.
Some  of  the  recommendations,  however,  may  raise  ques-
ions  as  they  are  a  long  way  from  current  practice  in  France,
nd  their  clinical  impact  has  not  been  truly  assessed  in  the
ontext  of  contemporary  cardiac  care  of  ACS  patients.  Two
f  them  are  important.
Because  of  the  dual  mechanism  underlying  admission
yperglycaemia,  the  text  justly  recommends  that  admission
lood  glucose  levels  should  not  be  used  to  deﬁne  the  pres-
nce  or  absence  of  diabetes  mellitus.  Instead,  it  proposes
hat  all  patients  without  known  diabetes  mellitus  undergo
n  oral  glucose  tolerance  test  1—4  weeks  after  the  acute
pisode.  This  is  extremely  far  from  current  practices,  and
side  from  the  potential  difﬁculty  in  organizing  such  a  gener-
lized  approach,  there  is  no  true  evidence  that  it  is  clinically
arranted.  Instead,  a  simple  check  of  the  HbA1c  levels  both
n  admission  and  somewhat  later  during  the  follow-up  of
atients,  for  instance  on  the  occasion  of  a  more  complete
ork-up  including  the  assay  of  blood  lipids  on  statin  ther-
py,  might  be  a  more  realistic  approach  to  detect  ‘hidden’
lucose  metabolism  disorders.
The  second  recommendation  pertains  to  the  systematic
se  of  insulin  therapy  and  to  the  interruption  of  all  other
ntidiabetic  agents  during  the  stay  in  the  intensive  care  unit.
gain,  this  is  far  from  real-world  practice  in  France:  in  the
ecent  FAST-MI  2010  (French  Registry  of  Acute  ST-Elevation
nd  Non—ST-Elevation  Myocardial  Infarction  2010),  carried
ut  at  the  end  of  2010  in  about  three-quarters  of  the  French
ntensive  cardiac  care  units,  only  46%  of  the  patients  with
n  admission  glycaemia  more  or  equal  to  180  mg/dL  and
3%  of  diabetic  patients  received  early  insulin  treatment,
hile  most  diabetic  patients  were  kept  on  their  current
ypoglycaemic  medications  (personal  data).  In  particular,
ne  wonders  what  is  the  rationale  for  stopping  antidia-
etic  oral  medications  when  admission  glycaemia  is  less
han  180  mg/dL,  which  was  the  case  in  over  half  of  the  dia-
etic  patients  admitted  with  either  ST-elevation  myocardial
nfarction  or  non-ST-elevation  myocardial  infarction  in  the
AST-MI  2010  registry.  .  .  In  fact,  the  Diabetes  Mellitus  Insulin
lucose  Infusion  in  AMI  (DIGAMI  2)  trial—the  most  recent
andomized  trial  assessing  the  impact  of  different  glucose-
owering  regimens  in  patients  with  AMI  [5]—failed  to  show
he  superiority  of  routine  insulin  therapy  compared  with  the
[N.  Danchin
ontinuation  of  oral  antidiabetic  agents  with  provisional  use
f  insulin  in  patients  admitted  with  AMI;  in  reality,  the  group
ith  the  best  long-term  outcome  was  the  one  who  under-
ent  conventional  management,  in  whom  only  14%  received
nsulin  at  the  acute  stage.
Likewise,  the  policy  regarding  metformin  treatment  in
atients  undergoing  coronary  angiography  (about  90%  of  the
atients  admitted  with  AMI  in  France  at  the  end  of  2010)  also
erits  debate.  In  contrast  with  the  current  consensus  doc-
ment,  the  recent  myocardial  revascularization  guidelines
f  the  European  Society  of  Cardiology/European  Association
f  Cardiothoracic  Surgery  [6]  note  that  there  is  little  scien-
iﬁc  evidence  for  recommending  stopping  metformin  before
oronary  angiography/percutaneous  coronary  intervention
PCI)  is  performed;  it  is  suggested  that  in  metformin-treated
atients,  renal  function  should  be  carefully  monitored  after
he  procedure  and  metformin  should  be  stopped  only  when
enal  function  deteriorates;  in  diabetic  patients  with  renal
ailure,  it  is  proposed  to  consider  stopping  metformin  48  h
efore  the  procedure  (grade  IIb  recommendation,  level  of
vidence  C).  Such  an  interruption,  however,  cannot  apply
o  patients  undergoing  primary  PCI,  and  the  beneﬁts  of  pri-
ary  PCI  should  certainly  not  be  denied  to  diabetic  patients
n  metformin  treatment  because  of  a potential  risk  of  lactic
cidosis.  In  fact,  the  FAST-MI  2005  and  FAST-MI  2010  registries
how  a  very  low  in-hospital  mortality  in  diabetic  patients  on
etformin-treated  with  primary  PCI,  and  provide  extremely
eassuring  data  in  this  regard  (personal  data).
Overall,  the  consensus  document  is  a  laudable  effort
o  focus  the  attention  of  cardiologists  on  the  importance
f  glucose  metabolism  disorders  and  diabetes  mellitus  in
atients  sustaining  an  acute  coronary  event.  As  in  all  expert
onsensus  documents,  some  of  the  measures  proposed  may
e  questionable,  emphasizing  the  fact  that  such  documents
hould  be  interpreted  as  general  rules  that  are  meant  to  be
dapted  to  each  individual  situation.
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